	US 11,839,660 B2
	Anti-transferrin receptor antibody and uses thereof
Romesh R. Subramanian, Framingham, MA (US); Mohammed T. Qatanani, Waltham, MA (US); Timothy Weeden, Waltham, MA (US); Cody A. Desjardins, Waltham, MA (US); Brendan Quinn, Boston, MA (US); and John Najim, Waltham, MA (US)
Assigned to Dyne Therapeutics, Inc., Waltham, MA (US)
Filed by Dyne Therapeutics, Inc., Waltham, MA (US)
Filed on Mar. 10, 2023, as Appl. No. 18/181,795.
Application 18/181,795 is a continuation of application No. 17/811,401, filed on Jul. 8, 2022, granted, now 11,672,872.
Claims priority of provisional application 63/220,043, filed on Jul. 9, 2021.
Prior Publication US 2023/0256113 A1, Aug. 17, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/68 (2017.01); C07K 16/28 (2006.01); A61P 21/00 (2006.01); A61K 39/00 (2006.01)

CPC A61K 47/6849 (2017.08) [A61K 47/6807 (2017.08); A61K 47/6811 (2017.08); A61K 47/6889 (2017.08); A61P 21/00 (2018.01); C07K 16/2881 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/55 (2013.01); C07K 2317/92 (2013.01)]

16 Claims

1. A method of producing an antibody that binds to human transferrin receptor (TfR), wherein the antibody is a Fab and comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 101 and a light chain comprising the amino acid sequence of SEQ ID NO: 90, and wherein the method comprises culturing a cell comprising a nucleic acid sequence encoding the heavy chain of the antibody and a nucleic acid sequence encoding the light chain of the antibody.